Identification of resistance mutations to crizotinib through circulating tumor cell (CTC) analysis in ALK-rearranged non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Pailler, Emma [1 ]
Faugeroux, Vincent [1 ]
Oulhen, Marianne [2 ]
Forcato, Claudio [3 ]
Laporte, Melanie [4 ]
Lecluse, Yann [4 ]
Lacroix, Ludovic [4 ]
NgoCamus, Maud [4 ]
Nicotra, Claudio [4 ]
Remon, Jordi [4 ]
Mezquita, Laura [4 ]
Planchard, David [4 ]
Soria, Jean-Charles [4 ]
Manaresi, Nicolo [3 ]
Besse, Benjamin [4 ]
Farace, Francoise [1 ]
机构：
[1] Univ Paris Saclay, Gustave Roussy, INSERM, U981, Villejuif, France
[2] INSERM, Gustave Roussy, U981, Villejuif, France
[3] Menarini Silicon Biosyst, Castel Maggiore, Italy
[4] Gustave Roussy, Villejuif, France
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3654
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib
    Nishino, Mizuki
    Wei, Zihan
    Mazzola, Emanuele
    Hino, Takuya
    Tseng, Shu-Chi
    Sanchez, Michelle E.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Awad, Mark M.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [22] Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it
    Drizou, M.
    Kotteas, E. A.
    Syrigos, N.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 658 - 666
  • [23] The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
    Srinivasamaharaj, Srividya
    Salame, Bilal Khameze
    Rios-Perez, Jorge
    Kloecker, Goetz
    Perez, Cesar A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1227 - 1233
  • [24] Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
    Elsayed, Mei
    Bozorgmehr, Farastuk
    Kazdal, Daniel
    Volckmar, Anna-Lena
    Sueltmann, Holger
    Fischer, Jurgen R.
    Kriegsmann, Mark
    Stenzinger, Albrecht
    Thomas, Michael
    Christopoulos, Petros
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] ALK-amplified circulating tumor cells as a surrogate marker for crizotinib benefit in ALK-rearranged non-small cell lung cancer patients.
    Pailler, Emma
    Remon, Jordi
    Oulhen, Marianne
    Borget, Isabelle
    Ross, Kirsty
    Auger, Nathalie
    Billiot, Fanny
    Ngocamus, Maud
    Planchard, David
    Soria, Jean-Charles
    Farace, Francoise
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Zhang, Yan
    Wang, Yan
    Li, Junling
    Hao, Xuezhi
    Ma, Di
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S377 - S377
  • [27] Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
    Canale, Matteo
    Petracci, Elisabetta
    Cravero, Paola
    Mariotti, Marita
    Minuti, Gabriele
    Metro, Giulio
    Ludovini, Vienna
    Baglivo, Sara
    Puccetti, Maurizio
    Dubini, Alessandra
    Martinelli, Giovanni
    Delmonte, Angelo
    Crino, Lucio
    Ulivi, Paola
    TRANSLATIONAL ONCOLOGY, 2022, 23
  • [28] Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: A case report
    Bearz A.
    Santarossa S.
    Manfrè A.
    Beltrame G.
    Urbani M.
    Sartor I.
    Da Ros V.
    Tirelli U.
    BMC Research Notes, 7 (1)
  • [29] Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer
    Sakakibara-Konishi, Jun
    Kitai, Hidenori
    Ikezawa, Yasuyuki
    Hatanaka, Yutaka
    Sasaki, Takaaki
    Yoshida, Ryohei
    Chiba, Shinichi
    Matsumoto, Shingo
    Goto, Koichi
    Mizugaki, Hidenori
    Shinagawa, Naofumi
    CLINICAL LUNG CANCER, 2019, 20 (05) : E555 - E559
  • [30] Optimal Treatment Strategy of Radiotherapy and Crizotinib for Patients with Brain Metastasis from ALK-Rearranged Non-Small-Cell Lung Cancer
    Sun, S.
    Kang, J.
    Sun, X.
    Men, Y.
    Yang, X.
    Yuan, M.
    Bao, Y.
    Ma, Z.
    Liu, Y.
    Li, J.
    Hui, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E392 - E392
12345